These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1552104)

  • 21. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study.
    Munkvad S; Jespersen J; Gram J; Kluft C
    J Am Coll Cardiol; 1991 Mar; 17(4):957-62. PubMed ID: 1900313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC
    Internist (Berl); 1992 May; 33(5):364-5. PubMed ID: 1612871
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombolysis: the need for a critical review.
    Monrad ES
    J Am Coll Cardiol; 1991 Nov; 18(6):1573-8. PubMed ID: 1939963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
    Wackers FJ; Terrin ML; Kayden DS; Knatterud G; Forman S; Braunwald E; Zaret BL
    J Am Coll Cardiol; 1989 Apr; 13(5):998-1005. PubMed ID: 2494246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolytic therapy for myocardial infarction.
    McNeill AJ; Adgey AA
    Lancet; 1988 Apr; 1(8591):938-9. PubMed ID: 2895857
    [No Abstract]   [Full Text] [Related]  

  • 26. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrinogen proteolysis and coagulation system activation during thrombolytic therapy.
    Owen J; Grossman B; Sobel J; Kudryk B
    Adv Exp Med Biol; 1990; 281():401-8. PubMed ID: 2129378
    [No Abstract]   [Full Text] [Related]  

  • 28. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
    Smith BJ
    J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolytic therapy.
    Collen D; Lijnen HR
    Ann N Y Acad Sci; 1991; 614():259-69. PubMed ID: 1902640
    [No Abstract]   [Full Text] [Related]  

  • 30. Tissue-type plasminogen activator for acute coronary thrombosis.
    Med Lett Drugs Ther; 1987 Dec; 29(754):107-9. PubMed ID: 3119965
    [No Abstract]   [Full Text] [Related]  

  • 31. [GUSTO (Global Utilization of Streptokinase & t-PA for Occluded Coronary Arteries): comparison of four therapeutic strategies in acute myocardial infarction. Washington, 30 April 1993].
    Internist (Berl); 1993 Jul; 34(7 Suppl):1-12. PubMed ID: 7591608
    [No Abstract]   [Full Text] [Related]  

  • 32. Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction.
    Amsterdam EA
    Pharmacotherapy; 1996; 16(5 Pt 2):137S-140S. PubMed ID: 8888101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 34. t-PA or not t-PA? That is the question.
    Joubert DW
    J Emerg Nurs; 1988; 14(4):240-1. PubMed ID: 3137389
    [No Abstract]   [Full Text] [Related]  

  • 35. Accelerated tPA versus streptokinase for suspected myocardial infarction: waiting for our Mountain Dew.
    McNutt R; Evans A
    Med Decis Making; 1995; 15(4):395-6. PubMed ID: 8544683
    [No Abstract]   [Full Text] [Related]  

  • 36. Innovative approaches to plasminogen activator therapy.
    Haber E; Quertermous T; Matsueda GR; Runge MS
    Science; 1989 Jan; 243(4887):51-6. PubMed ID: 2492113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The thrombolysis in myocardial infarction (TIMI) trial phase I and phase IIA pilot results. Implications for nursing.
    Brewer-Senerchia C
    Prog Cardiovasc Nurs; 1988; 3(4):128-36. PubMed ID: 2974593
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocardial infarction, thrombolytic therapy, and economics.
    Conti RC
    Clin Cardiol; 1993 Sep; 16(9):635. PubMed ID: 8242906
    [No Abstract]   [Full Text] [Related]  

  • 40. Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction.
    N Engl J Med; 1989 Sep; 321(10):687-9. PubMed ID: 2505074
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.